Cardiac transplantation outcomes in patients with amyloid cardiomyopathy

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

“…is provided in Table 1 8–25,34–77 . A graphical representation of the prevalence of cardiac amyloidosis across various populations subgroups is provided in Figure (and online supplementary Figure – focused version).…”

Heart transplantation in cardiac amyloidosis

“…Roiget al [26] reported sequential HTx/ASCT in five patients with AL cardiac amyloidosis: 2/5 died from progressive amyloidosis and 3/5 are alive, including one who developed progressive plasma cell dyscrasia that was successfully treated with highdose corticosteroids. Lacyet al [27] from the Mayo Clinic published a series of 11 patients undergoing sequential HTx/ASCT, reporting that 2/11 patients died from transplant-related toxicity and 3/11 died from progressive amyloidosis. The largest series of patients transplanted for CA was published in June 2021 from the United Network for Organ Sharing registry from 1987 to 2018, where the authors reported 313 patients affected by CA who underwent isolated HTx, with encouraging results [28] .…”

“…Another crucial point in this setting is related to the time of ASCT after HTx. Lacy et al [27] suggested to pursue ASCT in a time near to six months after HTx: sooner it may be difficult if the patient continues to require intensive immunosuppression, and later it may be too late for the risk of amyloidosis progression in other organs. This time-control strategy between HTx and ASCT could be another point of improvement in the survival of amyloidotic patients after HTx, in contrast to the previous analysis [33] .…”

Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis

“…With these advances, transplant outcomes have markedly improved, now approaching or equaling nonamyloidosis transplants in multiple studies ( Table 1 ) ( 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 ). At the same time, the frequency of transplants for amyloidosis has increased both in absolute numbers and as a percentage of total transplantations performed in the United States (0.3% in era 1 versus 1.2% in era 2) ( 6 ).…”